Researchers have developed a vitamin B12 analogue capable of bypassing the blood-brain barrier to deliver tumor-killing nitric oxide directly to glioblastoma cells. This preclinical breakthrough offers a potential solution to one of neuro-oncology's most persistent drug delivery challenges.
